

GENERAL ARTICLE

The landscape of *Parkin* variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease

Wei Yi¹, Emma J. MacDougall¹, Matthew Y. Tang¹, Andrea I. Krahn¹, Ziv Gan-Or², Jean-François Trempe³ and Edward A. Fon^{1,*}

¹McGill Parkinson Program, Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, H3A 2B4, Canada, ²Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, Department of Human Genetics, McGill University, Montreal, QC, H3A 1A1, Canada and ³Groupe de Recherche Axé sur la Structure des Protéines, Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, H3G 1Y6, Canada

*To whom correspondence should be addressed at: Montreal Neurological Institute, 3801 University Street, Montreal, QC H3A 2B4, Canada. Tel: +1 5143988398; Email: ted.fon@mcgill.ca

Abstract

Mutations in *Parkin* (*PARK2*), which encodes an E3 ubiquitin ligase implicated in mitophagy, are the most common cause of early-onset Parkinson's disease (EOPD). Hundreds of naturally occurring *Parkin* variants have been reported, both in Parkinson's disease (PD) patient and population databases. However, the effects of the majority of these variants on the function of *Parkin* and in PD pathogenesis remain unknown. Here we develop a framework for classification of the pathogenicity of *Parkin* variants based on the integration of clinical and functional evidence—including measures of mitophagy and protein stability and predictive structural modeling—and assess 51 naturally occurring *Parkin* variants accordingly. Surprisingly, only a minority of *Parkin* variants, even among those previously associated with PD, disrupted *Parkin* function. Moreover, a few of these naturally occurring *Parkin* variants actually enhanced mitophagy. Interestingly, impaired mitophagy in several of the most common *pathogenic* *Parkin* variants could be rescued both by naturally occurring (p.V224A) and structure-guided designer (p.W403A; p.F146A) hyperactive *Parkin* variants. Together, the findings provide a coherent framework to classify *Parkin* variants based on pathogenicity and suggest that several *pathogenic* *Parkin* variants represent promising targets to stratify patients for genotype-specific drug design.

Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease. Although most PD cases are sporadic, a fraction of cases are familial and caused by mutations in different genes (1). Mutations in the *Parkin* (*PARK2*) gene are the most

common cause of autosomal recessive early-onset Parkinson's disease (EOPD) and are believed to result in a loss of *Parkin* protein function (2). *Parkin* variants include rearrangements and copy number variations, such as deletions and duplications of exons, as well as single nucleotide variants that cause missense, nonsense or splice site mutations (3–5). Of these, missense

Received: January 21, 2019. Revised: April 2, 2019. Accepted: April 15, 2019

© The Author(s) 2019. Published by Oxford University Press. All rights reserved.

For Permissions, please email: journals.permissions@oup.com

variants are the most frequently reported in PD patients and, because they likely impede Parkin protein function rather than disrupting protein expression, may represent viable targets for therapies that enhance Parkin activity.

To envisage such genotype-specific therapies, the pathogenicity of the many *Parkin* variants in the population first needs to be determined. The American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG–AMP) have outlined five standard terminologies to describe variants identified in genes that cause Mendelian disorders (6). ‘Pathogenic’ and ‘likely pathogenic’ indicate a clear or very likely disease-causing effect of a variant, respectively. Conversely, ‘likely benign’ and ‘benign’ indicate variants that are not disease causing. Variants that cannot be assigned to one of these four groups are designated as ‘uncertain significance’. Over 200 *Parkin* missense variants have been deposited in public repositories (4,5,7,8). However, to date, only a minority of variants have been clearly annotated based on formal criteria.

A clear assignment of a *Parkin* variant requires integrating different lines of evidence that fall into two broad categories (9). Clinical evidence consists of the association or segregation of the variant with disease (or the absence of) in human cohorts or within families with multiple affected individuals. Functional evidence refers to the consequence(s) of the variant, using experimental assays that measure biochemical and cellular properties, as well as computational algorithms that model the effect(s) of the variant based on protein structure and function. Clinical evidence has a hierarchical relationship relative to functional evidence and prevails when a discrepancy or conflict arises between clinical and functional observations (9,10).

Parkin is a basally autoinhibited E3 ubiquitin (Ub) ligase, which contains an N-terminal Ub-like (Ubl) domain, connected through a linker to four zinc-coordinating domains, RING0, RING1, in-between-RING (IBR) and RING2, which form a core designated as the RORBR (11). Parkin is activated by PINK1, a mitochondrial kinase that is also implicated in EOPD (1). PINK1 accumulates on damaged mitochondria upon depolarization, where it phosphorylates nearby Ub (12–15). Parkin binds to phospho-Ub (pUb), which recruits Parkin to mitochondria and facilitates PINK1 phosphorylation of the Parkin Ubl, which in turn fully activates Parkin (16–18). Parkin then ubiquitinates multiple outer mitochondrial membrane targets, triggering a feed-forward amplification loop, that leads to the clearance of damaged mitochondria via autophagy (mitophagy) (reviewed in 19). While this activation cascade has been extensively characterized in mitophagy, whether and how Parkin might be activated during the many other cellular processes in which it has been implicated (20) is less clear. Indeed, *Parkin* missense variants found in patients have been shown to affect protein folding, Parkin autoubiquitination, protein–protein interactions or recruitment to mitochondria (21–26). However, as the pathogenic nature of most of these variants was not clear, the disease relevance of the functional alteration remained to be determined.

Here, we characterized all *Parkin* missense variants found in public databases, according to ACMG–AMP criteria. We then used a cell-based assay to quantify Parkin-mediated mitophagy and Parkin protein levels. We also applied structural simulations to explore the mechanisms underlying the observed functional alterations. Integrating these data, we find that only a minority of *Parkin* variants can be considered *pathogenic*. Interestingly, we identified several naturally occurring *Parkin* variants in the population that increase mitophagy in cells. Remarkably, such hyperactive *Parkin* variants were able to rescue the impaired

function of several common *pathogenic Parkin* variants. Our study suggests that several *pathogenic* PD-linked *Parkin* mutations represent promising targets amenable to genotype-specific drug design.

Results

Most *Parkin* missense variants lack sufficient clinical evidence to establish pathogenicity

To classify *Parkin* variants, we utilized Sherloc (semiquantitative, hierarchical evidence-based rules for locus interpretation), a classification framework that translates the ACMG–AMP standards to a set of discrete, but related, rules with refined weights (9). Clinical evidence was examined first, as it most directly relates to disease (9). Briefly, data from population databases, including minor allele frequency (MAF) and homozygote counts, and clinical records in PD-specific databases that report PD patients or unaffected family members carrying missense variants in *Parkin* were examined to assign weighted points as pathogenic or benign to each variant (Supplementary Material, Fig. 1). The pathogenic points and benign points were summed up separately and compared to preset thresholds to assign the variants to one of the five ACMG–AMP categories (Supplementary Material, Fig. 2).

From the PD-specific databases, PDmutDB (3,4) and MDSGene (5,27), we identified a total of 75 *Parkin* missense variants in PD patients (Fig. 1A). Most were absent or very rare in the control cohorts from the original reports, possibly due to the small sizes of the control cohorts. Therefore, we searched for the 75 variants in public population databases and found that 51 of them were reported in dbSNPs (7) and in the Exome Aggregation Consortium (ExAC), including high-quality variant calls across 60 706 human exomes (8) (Fig. 1A). In ExAC, we also found an additional 164 *Parkin* missense variants (Fig. 1A). The classification of the missense variants using clinical evidence allowed us to clearly designate 13 variants in PD as *pathogenic* or *likely pathogenic* and 10 variants as *likely benign* or *benign* (Fig. 1A and Table 1). The details of the points assigned to each variant are summarized in Supplementary Material, Table 1. Remarkably, large numbers of remaining variants lacked sufficient data to be assigned to either the *benign* or *pathogenic* categories and were therefore designated as of *uncertain significance* (Fig. 1A and Table 1; Supplementary Material, Table 1).

Parkin variants can be classified functionally in cells

Next, to determine the effects of the variants on Parkin function, we employed a cell-based assay to monitor and quantify mitophagy using fluorescence-activated cell sorting (FACS) in U2OS cells stably expressing inducible mt-Keima, a pH-sensitive fluorescent protein that is targeted to mitochondria and exhibits a large shift in its emission wavelength upon engulfment in the acidic compartment of lysosomes (28). U2OS cells express a very low level of endogenous Parkin, which is insufficient to mediate mitophagy in response to the mitochondrial potential uncoupler CCCP (29). In cells transiently expressing either wild-type (WT) Parkin or one of the *Parkin* variants fused to GFP, the shift in mt-Keima emission was measured upon 4 h of mitochondrial depolarization with CCCP (Supplementary Material, Fig. 3A). The GFP intensity in untreated cells was also quantified as a measure of steady-state Parkin protein levels (Supplementary Material, Fig. 3B). The level of CCCP-induced Parkin-mediated mitophagy




Figure 1. Parkin missense variants displayed a wide range of functional alterations. (A) 75 Parkin missense variants were reported in disease-specific databases (PDmutDB and MDSGene), 215 were reported in population databases (ExAC and dbSNP) and 51 were reported in both. Variants were assigned with one of the five standard ACMG terminologies: pathogenic (red), likely pathogenic (pink), likely benign (green), benign (olive) and uncertain significance (gray). (B and C) Quantification of the function of Parkin missense variants assigned as (B) Pathogenic (red), likely pathogenic (pink), likely benign (green), benign (olive) or (C) Uncertain significance (gray) by clinical evidence. Solid bars show mitophagy after 4 h of CCCP treatment quantified from mt-Keima signal in U2OS cells expressing GFP-Parkin variants normalized to WT Parkin. Hatched bars show GFP intensity of cells expressing GFP-Parkin variants normalized to WT Parkin. * $P < 0.05$, ** $P < 0.01$, in one-way ANOVA with Dunnett's post hoc test comparing the function of each variant with WT. $N = 3-7$.

and GFP intensity of the Parkin variants was normalized to that of WT Parkin.

We analyzed all the variants that were designated clinically as pathogenic or likely pathogenic, benign or likely benign (Fig. 1B). We also analyzed an additional 28 variants of uncertain signifi-

cance, including variants that were reported as homozygous or compound heterozygous in either the disease-specific databases or in population databases (Fig. 1C; Supplementary Material, Table 1). These variants represented the most common missense variants reported in the human population from public

Table 1. Classification of *Parkin* missense variants used in this study

| | Databases | <i>Parkin</i> variant | Assignment based on clinical evidence using Sherlock | Functional group from this study | Assignment based on clinical and functional evidence using Sherlock | Assignment from PDmutDB | Assignment from MDSGene |
|----|------------------------|-----------------------|--|----------------------------------|---|---------------------------|-------------------------|
| 1 | Disease and population | p.R42P | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 2 | Disease and population | p.V56E | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic | Probably pathogenic |
| 3 | Disease and population | p.K211N | <i>Pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 4 | Disease and population | p.C212Y | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 5 | Disease and population | p.C238W | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Probably pathogenic |
| 6 | Disease | p.C253Y | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Definitely pathogenic |
| 7 | Disease and population | p.G284R | <i>Pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic nature unclear | Probably pathogenic |
| 8 | Disease and population | p.T415N | <i>Pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 9 | Disease | p.C431F | <i>Pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 10 | Disease and population | p.C441R | <i>Pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Definitely pathogenic |
| 11 | Disease | p.T240R | <i>Likely pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 12 | Disease and population | p.R275W | <i>Likely pathogenic</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Definitely pathogenic |
| 13 | Disease and population | p.G430D | <i>Likely pathogenic</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 14 | Disease and population | p.A46T | <i>Likely benign</i> | 3 | <i>Likely benign</i> | Pathogenic nature unclear | Not mentioned |
| 15 | Disease and population | p.P153R | <i>Likely benign</i> | 4 | <i>Benign</i> | Pathogenic nature unclear | Not mentioned |
| 16 | Disease and population | p.M192L | <i>Likely benign</i> | 4 | <i>Benign</i> | Pathogenic | Not mentioned |
| 17 | Disease and population | p.R402C | <i>Likely benign</i> | 4 | <i>Benign</i> | Pathogenic nature unclear | Not mentioned |
| 18 | Disease and population | p.Q34R | <i>Benign</i> | 3 | <i>Benign</i> | Pathogenic nature unclear | Not mentioned |
| 19 | Disease and population | p.A82E | <i>Benign</i> | 4 | <i>Benign</i> | Pathogenic nature unclear | Not mentioned |
| 20 | Disease and population | p.S167N | <i>Benign</i> | 4 | <i>Benign</i> | Not pathogenic | Not mentioned |
| 21 | Disease and population | p.R334C | <i>Benign</i> | 5 | <i>Benign</i> | Pathogenic | Not mentioned |
| 22 | Disease and population | p.V380L | <i>Benign</i> | 4 | <i>Benign</i> | Not pathogenic | Not mentioned |
| 23 | Disease and population | p.D394N | <i>Benign</i> | 4 | <i>Benign</i> | Not pathogenic | Not mentioned |
| 24 | Disease and population | p.D18N | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic nature unclear | Not mentioned |
| 25 | Disease and population | p.R33Q | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic | Probably pathogenic |
| 26 | Disease and population | p.P37L | <i>Uncertain significance</i> | 5 | <i>Likely benign</i> | Pathogenic nature unclear | Possibly pathogenic |
| 27 | Disease and population | p.R42C | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic | Not mentioned |
| 28 | Disease and population | p.R42H | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic | Not mentioned |
| 29 | Disease | p.W54R | <i>Uncertain significance</i> | 3 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 30 | Disease and population | p.R104W | <i>Uncertain significance</i> | 3 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 31 | Disease | p.K161N | <i>Uncertain significance</i> | 2 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 32 | Disease | p.M192V | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic | Probably pathogenic |
| 33 | Population | p.V224A | <i>Uncertain significance</i> | 5 | <i>Likely benign</i> | Not mentioned | Not mentioned |

(Continued)

Table 1. Continued

| Databases | Parkin variant | Assignment based on clinical evidence using Sherlock | Functional group from this study | Assignment based on clinical and functional evidence using Sherlock | Assignment from PDmutDB | Assignment from MDSGene |
|---------------------------|----------------|--|----------------------------------|---|---------------------------|-------------------------|
| 34 Disease and population | p.R234Q | <i>Uncertain significance</i> | 5 | <i>Likely benign</i> | Pathogenic | Possibly pathogenic |
| 35 Disease and population | p.T240M | <i>Uncertain significance</i> | 2 | <i>Pathogenic</i> | Pathogenic | Probably pathogenic |
| 36 Population | p.V248I | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Not mentioned | Not mentioned |
| 37 Disease | p.C253F | <i>Uncertain significance</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Probably pathogenic |
| 38 Disease and population | p.R256C | <i>Uncertain significance</i> | 5 | <i>Likely benign</i> | Pathogenic nature unclear | Probably pathogenic |
| 39 Disease and population | p.D280N | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic | Not mentioned |
| 40 Disease | p.C289G | <i>Uncertain significance</i> | 1 | <i>Pathogenic</i> | Pathogenic | Definitely pathogenic |
| 41 Disease and population | p.E310R | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic nature unclear | Probably pathogenic |
| 42 Disease | p.G328E | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 43 Disease and population | p.R334H | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 44 Disease | p.T351P | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 45 Disease and population | p.G359D | <i>Uncertain significance</i> | 3 | <i>Uncertain significance</i> | Pathogenic | Not mentioned |
| 46 Disease and population | p.R366W | <i>Uncertain significance</i> | 4 | <i>Likely benign</i> | Pathogenic | Not mentioned |
| 47 Disease and population | p.R396G | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic nature unclear | Not mentioned |
| 48 Disease | p.C418R | <i>Uncertain significance</i> | 1 | <i>Pathogenic</i> | Pathogenic nature unclear | Probably pathogenic |
| 49 Disease and population | p.P437L | <i>Uncertain significance</i> | 2 | <i>Pathogenic</i> | Pathogenic nature unclear | Definitely pathogenic |
| 50 Disease and population | p.E444Q | <i>Uncertain significance</i> | 4 | <i>Uncertain significance</i> | Pathogenic | Not mentioned |
| 51 Disease and population | p.M458L | <i>Uncertain significance</i> | 5 | <i>Likely benign</i> | Pathogenic nature unclear | Not mentioned |

databases. Moreover, they were reported in 283 out of 309 families or isolated patients carrying Parkin missense variants in PD-specific databases.

The 13 Parkin variants classified as *pathogenic* or *likely pathogenic* based on clinical evidence all showed significantly decreased mitophagy (Fig. 1B). Seven variants (p.R42P, p.V56E, p.C212Y, p.C253Y, p.C238W, p.R275W and p.C441R) also showed decreased GFP intensity (Fig. 1B), suggesting reduced protein stability. Of these, all the variants in the RORBR of Parkin formed inclusions to different degrees, detected by fluorescence microscopy (Supplementary Material, Fig. 4). In contrast, the p.R42P and p.V56E variants in the Ubl domain showed lower overall GFP intensity without visible inclusions. Thus, for a subset of *pathogenic* and *likely pathogenic* Parkin variants, the observed defects in mitophagy are likely to stem from abnormal protein folding and reduced protein stability. In contrast, all 10 Parkin variants classified as *benign* and *likely benign* based on clinical evidence exhibited similar GFP intensity to WT and most, with 3 exceptions, also exhibited WT levels of Parkin-mediated mitophagy (Fig. 1B). p.Q34R and p.A46T displayed decreased mitophagy, whereas p.R334C showed an almost 3-fold increase (Fig. 1B). Of the 28 variants of *uncertain significance* based on clinical evidence, 14 displayed similar GFP intensity and mitophagy to WT Parkin (Fig. 1C). Nine displayed impaired mitophagy, three of which also showed decreased GFP intensity. Surprisingly, five variants showed increased mitophagy (Fig. 1C).

The wide range of changes in Parkin levels and mitophagy prompted us to ask whether we could classify the different vari-

ants into discrete groups. Variants that significantly decreased Parkin protein levels and mitophagy were assigned to Group 1 (Fig. 2A and Table 1). Variants that severely (0–30% of WT) or moderately (30–60% of WT) reduced Parkin-mediated mitophagy but displayed normal protein levels were assigned to Groups 2 and 3, respectively. Group 4 consisted of variants that were similar to WT, whereas Group 5 consisted of variants with increased (>140% of WT) Parkin-mediated mitophagy. Interestingly, all the *pathogenic* or *likely pathogenic* variants, classified based on clinical evidence, were assigned to Groups 1 or 2, whereas all the *benign* or *likely benign* variants fell into Groups 3, 4 or 5 (Fig. 2A and B). This suggested that the two functional measurements in our cell model could faithfully discriminate the pathogenic variants from the ‘non-pathogenic’ variants.

Integration of clinical and functional evidence refines the classification of Parkin variants

We next examined which clinical features were most strongly correlated with functional alterations. Among the variants that segregated with PD in families (Supplementary Material, Table 1), all but one (p.R33Q) severely altered Parkin function and were assigned to Groups 1 or 2 (Fig. 2C). However, it is important to note that segregation analysis was only possible in ~30 families, as most reports only involved single case reports without related family information (Supplementary Material, Table 1). Conversely, variants that were reported as




Figure 2. Integration of clinical and functional evidence refined the classification of Parkin variants. (A) Functional alteration of variants assigned as *pathogenic* (red), *likely pathogenic* (pink), *likely benign* (green), *benign* (olive) and of *uncertain significance* (gray) based on clinical evidence were plotted for mitophagy activity on the X axis and GFP intensity on the Y axis. Functional alteration segregated into five groups, indicated by black boxes. 1. Significantly decreased mitophagy activity and GFP intensity compared with WT. 2. Severely decreased mitophagy activity with WT GFP intensity. 3. Moderately decreased mitophagy activity with WT GFP intensity. 4. WT mitophagy activity and GFP intensity. 5. Significantly increased mitophagy activity with WT GFP intensity. (B) Quantification of the variants within each of the functional groups from (A). (C) Quantification of variants within the functional groups described in (A) according to their segregation or lack of segregation with PD in families. (D) Quantification of variants within the functional groups described in (A) according to the observation of the variant as more than one homozygote (blue), one homozygote (light-blue) or no homozygotes (white) in ExAC. (E) Quantification of variants within the functional groups described in (A) according to the observation of the variant in PD patients. (F) Quantification of variants within the functional groups described in (A) according to their classification based on clinical and functional evidence.

homozygotes in ExAC were frequent in Groups 3, 4 and 5 and not assigned to Groups 1 or 2 (Fig. 2D). Notably, several variants that were reported in PD patients as homozygous or compound heterozygous, nonetheless displayed WT Parkin levels and function (Fig. 2E). Most had relatively high MAFs

in ExAC (Supplementary Material, Table 1), suggesting their presence in patients was due to their high prevalence rather than pathogenicity. Taken together, our data show that variants segregating with disease in families impair Parkin function (Groups 1 and 2), whereas variants that occur as homozygotes




Figure 3. Steric clashes in structural simulations predicted the dysfunction of Parkin variants. (A) Schematic representation of Parkin missense variants on Parkin protein 2D structure. Each circle indicates a missense variant. The location of the variant on the 2D sequence was plotted in the X axis with dotted lines separating the Parkin domains. The functional groups described in Figure 2A were plotted on the Y axis. The colors indicate the type of clash introduced by the missense variant from structural simulation. (B) Distribution of the variants from (A) within functional groups according to the type of clash they introduce. (C) Structure of human Parkin bound to pUb (PDB 5n2w) was used to illustrate the impact of the R42P mutation. Substitution of the arginine side chain (black) to proline (white) introduced major clashes (red disks), which would destabilize the β -sheet in the Ubl. (D) Substitution of the arginine side chain (black) to histidine (white) introduced mild clashes (red and green disks). (E) Substitution of the arginine side chain (black) to cysteine (white) did not introduce any clashes.

in ExAC did not severely reduce Parkin function (Groups 3, 4 and 5).

Next, we devised a scoring scheme, based on Sherlock, to assign benign or pathogenic points (Supplementary Material, Fig. 5), according to the functional group to which the Parkin variants were assigned in the cellular assays (Fig. 2A). The pathogenic points and benign points were then added to the corresponding points from the clinical evidence in order to obtain combined pathogenic and benign scores from all evidence for the final annotation of each variant (Table 1; Supplementary Material, Table 1). Using these combined clinical and functional scores, all the likely pathogenic variants from clinical evidence were reclassified as pathogenic (Table 1). Additionally, three likely benign variants were reclassified as benign (Table 1). Most of the variants of uncertain significance were reclassified as likely benign, while six were reclassified as pathogenic and nine remained of uncertain significance (Table 1). In summary, all variants that caused functional alterations assigned to Groups 1 and 2, as measured in our experimental assay, were reclassified as pathogenic, whereas most variants assigned to functional Groups 3, 4 and 5 were reclassified as either benign or likely benign (Fig. 2F).

Structural analysis of Parkin variants reveals pathogenic mechanisms

As the structure of Parkin is known, we modeled the effects of variants on the reported crystal structures of Parkin to gain insight into the mechanisms underlying the functional changes. The structures of autoinhibited Parkin, pUb-bound Parkin, pUb-bound phospho-Parkin and pUb-E2 enzyme-bound phospho-Parkin were used as they depict Parkin in its different states of activation (17,18,30,31).

Most variants in functional Groups 1 and 2 were predicted to introduce steric clashes with nearby residues in at least one of the Parkin structures. In contrast, most variants in Group 4, which displayed similar function as WT Parkin, introduced no major clashes and did not affect interactions (Fig. 3A and B). However, mild clashes were observed in a few cases, suggesting that some degree of steric clashing could be tolerated and possibly be compensated for by local conformation changes to maintain overall protein function. For example, three variants at Arg42 were analyzed. Mutation of Arg42 to proline introduced major clashes, whereas substitution to histidine introduced mild clashes and there was no clash introduced by substitution to




Figure 4. Structural analysis of Parkin variants revealed various pathogenic mechanisms. (A) Pathogenic variants were mapped onto the 3D structure of human Parkin bound to pUb (PDB 5N2W). The side chains of the amino acids substituted by the variants were highlighted in black. The blue spheres represent the phosphate of pUb. The gray spheres represent zinc. The color of the text indicates the type of disruption to Parkin caused by the variant. (B) Close-up view of pUbl-RING0 interface in the structure of fly pParkin bound to phospho-Ub (PDB 6DJX). Lys161 and Lys211 form ionic interactions with the phosphate on Ser65 of the pUbl. Mutations of these lysine residues would weaken the pUbl-RING0 interaction, preventing activation of Parkin. (C) Close-up view of the pUb:RING1 interface in human Parkin bound to pUb (PDB 5N2W). The G284R variant in Parkin RING1 would introduce major clashes with pUb, disrupting the interaction. (D) Close-up view of Arg275 in human Parkin bound to pUb (PDB 5N2W). Arg275 interacts with Glu321 in the helix that interacts with pUb. Mutation to a tryptophan (white) would introduce clashes with this helix as well as Ser10 in the Ubl domain.

cysteine (Fig. 3C–E). Congruently, only p.R42P was classified as *pathogenic* based on clinical criteria and functional impairment in cell-based assays (Fig. 1B and C), consistent with the simulations that showed this mutation unfolded the Ubl domain (23,32). These simulated steric clashes nicely illustrate how different amino acid substitutions at a given residue could lead to distinct functional impairment.

The effects of variants in Groups 1 and 2 likely disrupt several different aspects of Parkin function (Fig. 4A). Seven variants involve cysteine residues that coordinate zinc, and their mutation would result in overall misfolding of the Parkin protein (30). Five variants alter key motifs mediating ubiquitination of substrates, including steric clashes with the E2 binding site on RING1 (p.T240R and p.T240M), and residues implicated in thioester transfer of Ub in the catalytic RING2 domain (p.T415N, p.G430D and p.C431F) (33). These types of alterations are likely to cause a complete loss of Parkin

function in either PINK1-Parkin-mediated mitophagy or other potential Parkin pathways. Four variants specifically localize to motifs implicated in the conformational change that occurs during activation by PINK1. p.K161N and p.K211N introduce no or mild steric clashes, but substitution of the basic lysine residue to the neutral asparagine eliminates the interaction with the acidic phosphate in pUbl [Fig. 4B and (17,18)]. p.G284R introduces major clashes with pUb, thus impairing binding and recruitment to mitochondria (Fig. 4C). p.R275W disrupts interaction with the helix that mediates pUb binding (Fig. 4D). This is predicted to destabilize Parkin, consistent with the observed decreased steady-state protein level and the presence of cellular inclusions (Fig. 1B; Supplementary Material, Fig. 4). This helix becomes more exposed following pUb binding and may also be involved in the allosteric release of the Ubl during activation [Fig. 4D and (17,18)]. The clashes caused by p.R42P and p.V56E are predicted to misfold the Ubl domain




Figure 5. Structure-guided designer hyperactive Parkin mutants can rescue mitophagy in pathogenic variants. (A) Quantification of induced mitophagy after 4 h of CCCP treatment in U2OS cells expressing WT GFP-Parkin, pathogenic missense variants or W403A or F146A in cis with WT or pathogenic variants. Mitophagy mediated by each Parkin missense variant was normalized to that of WT Parkin in each replicate. * $P < 0.05$, ** $P < 0.01$, in two-way ANOVA with Dunnett's post hoc test comparing the function of each variant with the variant in cis with W403A or F146A. $N = 3-7$. (B) The number of families or individuals with PD carrying the pathogenic missense variants for which mitophagy was or was not rescued by the designer mutations are shown. (C) The sum of the MAF in ExAC of the pathogenic missense variants for which mitophagy was or was not rescued by the designer mutations are shown.

and thus destabilize the protein, as demonstrated earlier for p.R42P (23). Concurrently, p.R42P and p.V56E may also hinder conformational change during activation by preventing Ubl phosphorylation (34) and the binding of pUbl to RING0 (17). One variant, p.P437L, introduced very mild steric clashes in RING2 in the Parkin structure, and the exact molecular mechanism of p.P437L in causing decreased mitophagy remains unclear.

Several variants in functional Group 3 that moderately decreased Parkin-mediated mitophagy might also act by hindering Parkin activation by PINK1. p.A46T could disrupt the interaction of pUbl with RING0 (Supplementary Material, Fig. 6A). p.R104W induced clashes to the newly identified activation element (ACT), which binds RING0 and helps stabilize the interaction with pUbl and RING0 [Supplementary Material, Fig. 6B and (18)]. p.G359D disrupted the glycine-rich loop in the IBR domain that interacts with pUb (Supplementary Material, Fig. 6C). These clashes may be compensated by minor local conformation changes and thus lead to milder disruptions in mitophagy and protein stability.

Structure-guided designer hyperactive Parkin mutants can rescue mitophagy in pathogenic variants

We next hypothesized that some of the pathogenic variants may represent targets for genotype-specific therapy. As a proof of concept, we introduced two artificially designed mutations, W403A and F146A, which destabilized the REP (repressor element of Parkin):RING1 and the RING0:RING2 interfaces, respectively. Both mutations have been shown to accelerate mitophagy by promoting the conformational changes that

occur at these interfaces during Parkin activation by PINK1 (29,30). We tested whether these hyperactive mutations could rescue the mitophagy defects seen in the pathogenic Parkin variants. As reported previously, mutating F146A or W403A alone enhanced mitophagy compared to WT Parkin (Fig. 5A) (29). Remarkably, introducing F146A or W403A in cis with p.R42P, p.V56E, p.K161N, p.K211N, p.R275W, p.P437L or p.T240M rescued mitophagy (Fig. 5A). Variants p.R42P, p.V56E and p.R275W each lower Parkin levels, likely by disrupting protein stability (Fig. 1B). However, introduction of F146A or W403A did not restore Parkin levels to WT (Supplementary Material, Fig. 7), suggesting the rescue of mitophagy was mediated by Parkin activation *per se* rather than by enhancing Parkin protein stability. The pathogenic variants p.K161N and p.K211N are involved in binding the pUbl during activation (17,18). The fact that both these variants can be rescued by F146A or W403A suggests that destabilization of the REP:RING1 or the RING0:RING2 interface can bypass the tethering of the Ubl to RING0, which occurs during Parkin activation.

Introducing F146A or W403A in cis with the variants could not rescue any of the seven pathogenic cysteine variants involved in zinc coordination (Fig. 5A). Thus, the severe disruption of Parkin folding and stability induced by mutating these cysteines are likely to preclude them from being good candidates for therapeutic rescue by hyperactivation (Fig. 1B and C). Similarly, most variants that disrupted key catalytic sites could not be rescued (Fig. 5A). Also, p.G284R could not be rescued as it disrupts binding to pUb, which is an essential receptor for recruiting Parkin to damaged mitochondria (35). Interestingly, whereas both p.T240M and p.T240R are predicted to interfere with E2 Ub-conjugating enzyme binding to RING1 and showed similar severe defects in




Figure 6. Structural basis for the effects of the naturally occurring hyperactive Parkin variants. (A) Close-up view of R234Q and R256C variant sites in the structure of human Parkin bound to pUb (PDB 5N2W). Arg256 forms a hydrogen bond with Glu402, and its mutation to a cysteine would destabilize the REP:RING1 interaction, similar to W403A. The side-chain of Arg234 also stacks with the indole ring of Trp403. (B) Close-up view of M458L variant site in the RING0:RING2 interface (PDB 5N2W). M458L introduced major clashes that would destabilize the RING0:RING2 interaction, similarly to F146A. (C) Close-up view of V224A variant site (PDB 5N2W). Val224 interacts with pUb and forms van der Waals force interactions with Asn60. Mutation to alanine could modulate the affinity for pUb.

mitophagy, only the former could be rescued by F146A or W403A (Fig. 5A). Both variants created clashes in the E2 binding site (Supplementary Material, Fig. 8A and B). However, Arg240 created a positive charge at the interface, increasing the electrostatic repulsion of E2. Methionine is less bulky and neutral, and its flexibility could allow some weak interactions with E2 to remain, perhaps explaining its rescue by F146A or W403A (Supplementary Material, Fig. 8C–E).

Overall, the defects in mitophagy of 7 of the 19 pathogenic variants could be rescued by the designed activating mutations. These seven variants are responsible for over 75% of the reported PD patients carrying pathogenic missense variants (Fig. 5B) and were the most frequent pathogenic missense variants in the general population (Fig. 5C). Mimicking the effects of F146A or W403A could therefore be a useful starting point for designing treatments for patients with PD caused by these Parkin variants.

Characterization of naturally occurring hyperactive Parkin variants

We identified six naturally occurring variants that, considering all the evidence, were classified as likely benign or benign and showed enhanced Parkin-mediated mitophagy (Fig. 1B and C and Table 1). The Parkin structure shows that Arg234 and Arg256 are located at the interface between the REP and RING0. The p.R234Q and p.R256C variants are predicted to destabilize the interface, thus mimicking the W403A designer mutant

used above (Fig. 6A). Additionally, p.M458L may destabilize the RING0:RING2 interface, mimicking the effects of our other designer mutation, F146A (Fig. 6B). Thus, based on structural predictions, three of the six naturally occurring variants are likely to activate Parkin via mechanisms akin to those involved in the hyperactive mutants designed previously (29). Because these variants occur naturally in the population, our findings demonstrating rescue of mitophagy suggest that targeting these sites and mechanisms are likely to be tolerated and potentially therapeutic in PD. p.P37L also moderately increased Parkin-mediated mitophagy, but the structural basis of the increased activity was unclear, as this variant does not create any steric clash and thus should not affect interactions of the Ubl with RING1 or interactions of the pUbl with RING0 (Supplementary Material, Fig. 9A and B). Mutation of Arg334 to a cysteine could affect the coordination of a nearby zinc in the IBR, which may stabilize the interaction with pUb and thereby enhance Parkin activity (Supplementary Material, Fig. 9C).

Unlike the five other naturally occurring hyperactive variants, p.V224A has not been reported in PD patients (Supplementary Material, Table 1) and showed the highest (almost 3-fold above WT) Parkin-mediated mitophagy activity (Fig. 1C). The Val224 residue is localized in the pUb-binding pocket, with its side chain facing toward the phosphorylated Ser65 residue of pUb, and the mutation to alanine could modulate the affinity of Parkin for pUb (Fig. 6C). We therefore examined the ability of hyperactive p.V224A to rescue the function of the pathogenic




Figure 7. The naturally occurring Parkin p.V224A hyperactive variant rescued mitophagy in several pathogenic variants. (A) Quantification of GFP intensity from GFP signal by FACS in untreated cells expressing WT GFP-Parkin, pathogenic missense variants or p.V224A in cis with WT or pathogenic variants. The GFP intensity for each Parkin missense variant was normalized to that for WT Parkin in each replicate. (B) Quantification of induced mitophagy after 4 h of CCCP treatment in cells expressing WT GFP-Parkin, pathogenic missense variants or p.V224A in cis with WT or pathogenic variants. Mitophagy mediated by each Parkin missense variant was normalized to that of WT Parkin in each replicate. * $P < 0.05$; ** $P < 0.01$, in two-way ANOVA with Dunnett's post hoc test comparing the function of each variant with variant in cis with p.V224A. $N = 3-7$.

variants. Introducing the p.V224A variant in cis did not affect the protein level of most pathogenic variants, except for p.G284R (Fig. 7A). This may stem from an additive destabilizing effect of the double mutant on Parkin folding as both p.V224A and p.G284R are located within the same pUb-binding motif. Introducing the p.V224A variant partially rescued the mitophagy defects of p.R42P, p.V56E and p.K161N (Fig. 7B). How the predicted effects of V224A on pUb binding could partially compensate for defects in Ubl- and pUbl-mediated activation by p.R42P, p.V56E and p.K161N remains to be elucidated. p.V224A could not rescue the mitophagy deficit in p.R275W and p.G284R variants, nor could it rescue any of the remaining pathogenic variants that directly damaged catalytic activity and zinc coordination (Fig. 7B). Compared with F146A or W403A, p.V224A was less effective at rescuing the pathogenic variants, suggesting that the pUb-binding site may be a less promising target for activating mitophagy than releasing the autoinhibited conformation of Parkin.

Discussion

Parkin mutations are the most common cause of recessive early-onset PD (EOPD) (2). Although Parkin loss of function is well established in EOPD (5,36), causality for any given missense variant has been more difficult to ascertain. In this study, we have integrated clinical, experimental and structural modeling approaches to map out the landscape of Parkin variants in the general population and in PD patients. Our hope is that this

work will help provide a more cohesive framework to guide basic science studies exploring the molecular and cellular functions of the PINK1/Parkin pathway and to guide clinicians caring for patients carrying specific Parkin variants. We also hope that the work will inform structure-based drug design to develop Parkin activators and help guide Parkin allele- and genotype-specific clinical studies.

For the over 200 Parkin variants reported in public databases (3,5,8), we found that only a minority of variants could be clearly designated as likely pathogenic, pathogenic, likely benign or benign based on clinical evidence alone. While this may not seem surprising for variants found only in population databases such as ExAC, where accompanying clinical information is scant, we found a similar situation for variants reported in patients. Indeed, 52 out of the 75 variants reported in PDmutDB and MDSGene remained of uncertain significance after having been subjected to the Sherlock algorithm, the variant classification framework derived from ACMG standards that we used in this study. In the case of PDmutDB, this difference likely stems from a lack of utilization of population data for assignments and from the fact that many cases were not yet reported in 2012 when PDmutDB was published. In the case of MDSGene, whereas benign or likely benign variants were not included, the assignments for pathogenicity are quite similar to ours except for some variants, which may stem from a lack of functional data and differences in scoring for clinical case reports. The overarching message from these observations is that the mere presence of Parkin variants in PD patients, PD kindreds or PD-specific

databases should be interpreted with caution and not automatically taken to imply pathogenicity. Rather, we propose that clinical evidence available for new variants should be subjected to the same rigorous classification scheme presented here to determine pathogenicity.

In addition to analyzing clinical evidence, we extensively characterized the cellular effects of the 51 *Parkin* variants most commonly found in patient and population sequencing databases. As it is currently not feasible to test every variant using cell-based functional assays, we prioritized variants for functional testing based on available clinical data and variant frequency. To our knowledge, a systematic analysis integrating clinical evidence with cellular function, on this scale, has not been reported previously for *Parkin* (21–26,37,38). Notably, all the variants designated as *pathogenic* or *likely pathogenic* based on clinical evidence also displayed severe mitophagy defects in cells (functional Groups 1 and 2). Conversely, all variants designated clinically as *benign* or *likely benign* displayed mitophagy function in the WT range or showed only a slight reduction (functional Groups 3, 4 and 5). While this may seem *a priori* as self-evident, several alternative functions of *Parkin* in cells have been proposed and the role of mitophagy in PD has yet to be definitively established (20,39–41). Thus, while this work does not refute the biological importance of such alternative functions, the tight correlation between the clinical impact of the variants and their effects on mitophagy provides further evidence that mitophagy can be used as a robust and disease-relevant readout of *Parkin* function that likely reflects a key pathogenic process in PD.

Assignment of the *Parkin* variants to functional groups in cells allowed us to determine which clinical features best correlate with and could be used to predict pathogenicity. Segregation of variants with PD in families and observation of homozygotes in ExAC turned out to be very strong predictors for pathogenicity or the absence of pathogenicity, respectively. In contrast, the mere report of PD patients with one or two *Parkin* variants or the absence of these variants in control cohorts or population databases should not be automatically taken to imply pathogenicity. Perhaps more importantly, integrating clinical with functional evidence from cells allowed us to re-assign 19 of the 28 variants, designated as of *uncertain significance* based on clinical evidence alone, to one of the benign and pathogenic categories. It also allowed us to reclassify six of the 'likely' variants to their respective more definitive *benign* and *pathogenic* categories. Together, these findings attest to the power of using this sort of iterative combined clinical and experimental approach to stratify variants.

It remains unclear whether the many *Parkin* variants found in the population, including functionally pathogenic variants found in the heterozygous state, serve as risk factors for the development of idiopathic PD. However, as Sherlock is based on the ACMG–AMP guidelines that are developed for annotation of variants associated with Mendelian diseases (9), we could not utilize this algorithm to test this hypothesis. Moreover, because the mitophagy assay is not optimized to detect the types of dosage effects that one would predict in heterozygous states, it is very difficult to address this very important question using the approaches in the current study.

Given what is already known about the structure and function of the *Parkin* protein, the work enables in-depth mechanistic exploration of how *pathogenic* variants can lead to dysfunction. This is something that has been sorely lacking and may have important implications for how best to target *Parkin* and design activators for future therapy. For most of the *pathogenic* variants,

the mechanisms by which they interfere with function can be rationalized based on the *Parkin* structure. As an important proof of concept, we showed that the function of several pathogenic *Parkin* variants, defective in mitophagy in cells, could be rescued when expressed *in cis* with mutations that have been previously designed to enhance *Parkin* activity (29,30). This provides further stratification according to therapeutic potential. For instance, alterations in residues involved in zinc coordination, in catalytic activation or in pUb binding could not be rescued. In contrast, alterations in residues involved in Ubl folding or in the pUbl-RING0 interface in the active *Parkin* structure could be fully rescued, suggesting that therapeutics that disrupt the REP-RING1 or the RING0-RING2 interfaces could potentially bypass these defects (17,18). Importantly, many of the most commonly occurring variants were the ones that could be rescued, something that bodes well for patients carrying these variants, should a therapeutic mimicking W403A or F146A become available.

One of the most surprising findings of our study was that several naturally occurring variants exhibited a 1.5- to almost 3-fold enhancement in *Parkin*-mediated mitophagy in our assay. This could not simply be explained by increased *Parkin* protein levels or by the fact that our assay involved overexpression. Indeed, except for certain pathogenic variants that destabilized *Parkin*, most variants, including the hyperactive ones, displayed steady-state levels that were very close to WT levels. These hyperactive variants provide an important proof of principle that there are, presumably healthy, individuals in the population living with enhanced *Parkin* activity. The strongest activating variant was V224A, which increases mitophagy by nearly 3-fold and occurs very near the site for pUb binding. This was surprising as pUb binding serves as a critical receptor to recruit *Parkin* to mitochondria and, to date, every reported mutation in this motif, abolished or dramatically reduced mitophagy. Moreover, when expressed *in cis*, V224A partially rescued certain, but not all, of the mutants that were rescued by W403A and F146A. In the future, it will be important to test whether this involves an enhancement in pUb binding or some other downstream allosteric effect. Similarly, it will be important to determine the mechanisms by which the two remaining hyperactive variants, P37L and R334C, enhance *Parkin* function. Moreover, as we only sampled 51 of the over 200 *Parkin* variants in the population in this study, it is conceivable that other yet-to-be-discovered hyperactive variants will provide further mechanistic insights into *Parkin* activation and help identify additional therapeutic sites within the protein.

Materials and Methods

Classification of *Parkin* missense variants

We utilized Sherlock (semiquantitative, hierarchical evidence-based rules for locus interpretation), a variant classification framework derived from ACMG standards to assign *Parkin* missense variants into five categories: *pathogenic*, *likely pathogenic*, *benign*, *likely benign* and of *uncertain significance* (9). We considered two broad categories of evidence for the classification, clinical and functional. The procedures for evaluating and scoring these lines of evidence are summarized as root-decision trees in [Supplementary Material, Figures 1, 2 and 5](#).

For clinical evidence, information regarding missense variants in *Parkin* reported in the population database ExAC (<http://exac.broadinstitute.org/gene/ENSG00000185345>) (8) and the disease-specific databases, PDmutDB (<http://www.molgen.vib-ua.be/PDmutDB>) (3) and MDSGene (<http://www.mdsgene>

org) (5), were searched. We also searched dbSNP (<http://www.ncbi.nlm.nih.gov/snp>) and the Exon Variant Server (EVS, <http://evs.gs.washington.edu/EVS/>) for missense variants that were found in the disease databases, but not in ExAC. The homozygote count, MAF in ExAC and maximal MAF in dbSNP, EVS and subpopulations in ExAC were calculated and used to assign points to the variants according to the decision tree in [Supplementary Material, Figure 1A](#). The clinical cases reported in PDmutDB and MDSGene were evaluated according to the decision tree in [Supplementary Material, Figure 1B and C](#). The original references were traced back for the indexed families or individuals reported in these databases. Indexed cases reported in both databases cited from the same reference were only evaluated once. Indexed cases reported in a more recent paper showing the same information (same number of family members with same genotype and phenotype) as a case in an older reference were considered as the same family and the older report was used.

For functional evidence, the effects of the variants in the cellular assay were assigned points according to the decision tree in [Supplementary Material, Figure 5](#). We imposed a 2.5-point cap on functional evidence to ensure that functional data, which lacked supporting clinical evidence, would not be sufficient on its own to reach the threshold required (3 benign points or 4 pathogenic points; [Supplementary Material, Figure 2](#)) to assign a variant to the *pathogenic* or *benign* categories (9).

Cell culture, cloning and mutagenesis

Human osteosarcoma U2OS cells were a gift from Dr Robert Sreaton (Sunnybrook Research Institute). U2OS cells stably expressing mt-Keima (a gift from A. Miyawaki, Laboratory for Cell Function and Dynamics, Brain Science Institute, RIKEN, Japan) were created by transfecting plasmid DNA using jetPRIME (Polyplus, New York, NY), followed by selection with G418 for 2 weeks and sorting using flow cytometry (29). Cells were maintained in DMEM supplemented with 10% fetal bovine serum, 4 mM L-glutamine and 0.1% Penicillin/Streptomycin, in a 37°C incubator with 5% CO₂. All GFP-Parkin variants were generated using PCR mutagenesis on the GFP-Parkin WT plasmid (addgene#45875) according to the manufacturer's protocol (Agilent Technologies, Santa Clara, CA). Constructs were verified by Sanger sequencing.

Mitophagy and GFP intensity measurement by FACS

U2OS cells stably expressing ecdysone-inducible mt-Keima were induced with 10 nM ponasterone A and transiently transfected with WT or variant GFP-Parkin for 24 h and treated with DMSO or 20 μM CCCP for 4 h and followed immediately by flow cytometry. To minimize transfection efficiency variation, the same amount of GFP-Parkin WT or variant plasmid was utilized and only the population of GFP-positive cells was analyzed in the subsequent FACS data processing. For flow cytometry, cells were trypsin digested, washed and resuspended in PBS prior to their analysis on an LSR Fortessa (BD Bioscience, San Jose, CA) equipped with 405 and 561 nm lasers and 610/20 filters (Department of Microbiology and Immunology Flow Cytometry Facility, McGill University). Measurement of mt-Keima was made using a dual-excitation ratiometric pH calculation where pH 7 was detected through the excitation at 405 nm and pH 4 at 561 nm (29). For each untreated sample, 75 000 events were collected and single GFP-Parkin-positive cells were subsequently gated for

quantification of the geometric mean of the GFP signal as a measure of steady-state Parkin protein levels. The value for each Parkin missense variant was normalized to that for the WT in each experiment. For each untreated and treated sample, single GFP-Parkin-positive, mt-Keima-405 nm-positive cells were subsequently gated. The percentage of cells with an increase in the 405:561 nm ratio in mt-Keima was quantified. The percentage in treated cells minus the percentage in untreated cells was calculated as the induced Parkin-mediated mitophagy. The induced mitophagy for each Parkin missense variant was normalized to that for WT in each repeat. Data were analyzed using FlowJo v10.1 (Tree Star, Ashland, OR).

Modeling of Parkin structures, modifications and variants

The structures of human Parkin bound to pUb (PDB 5N2W), rat parkin (PDB 4ZYN), human phospho-parkin bound to phospho-Ub (PDB 6GLC) and fly pParkin-pUb-UbcH7 complex (PDB 6DJX) were analyzed using PyMOL version 1.5 (Schrödinger, New York). Mutations and clashes were simulated using the mutagenesis wizard toolbox. The presence of more than three simulated significant clashes (red disks) was taken to indicate major clashes. One to three significant clashes (red disks) together with other slight clashes (brown and green disks) were considered as minor clashes. Polar contacts within 4 Å distance of the residue were explored for characterizing interactions.

Statistical analysis

For statistical analysis of mitophagy and protein levels, one-way analysis of variance (ANOVA) with Bonferroni *post hoc* tests were performed. To determine the ability of hyperactive mutants to rescue Parkin variants, two-way ANOVA and Bonferroni *post hoc* test comparing row factors among the single or double mutations were performed. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Supplementary Material

[Supplementary Material](#) is available at HMG online.

Acknowledgements

We thank members from the Trempe and Fon laboratories, as well as Kalle Gehring for useful discussion and comments. The flow cytometry work/cell sorting was performed in the McGill Life Science Complex Flow Cytometry Core Facility supported by funding from the Canadian Foundation for Innovation.

Conflict of Interest statement. None declared.

Funding

Parkinson Society Canada (Basic Science Postdoctoral Fellowship to W.Y.); Canadian Institutes of Health Research (154301 to E.A.F.).

Author contributions

W.Y. performed cloning, genetic analysis and experiments in cells. E.J.M., M.Y.T. and A.I.K. assisted with cloning and experiments in cells. Z.G.-O. assisted with genetic analysis. J.-F.T. assisted with all the structural simulations. W.Y., E.J.M., M.Y.T.,

Z.G-O, J.F.T. and E.A.F. participated in the design of experiments, data analysis and preparation of the manuscript.

References

- Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkman, J., Schrag, A.E. and Lang, A.E. (2017) Parkinson disease. *Nat. Rev. Dis. Primers*, **3**, 17013.
- Koros, C., Simitsi, A. and Stefanis, L. (2017) Genetics of Parkinson's disease: genotype-phenotype correlations. *Int. Rev. Neurobiol.*, **132**, 197-231.
- Nuytemans, K., Theuns, J., Cruts, M. and Van Broeckhoven, C. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. *Hum. Mutat.*, **31**, 763-780.
- Cruts, M., Theuns, J. and Van Broeckhoven, C. (2012) Locus-specific mutation databases for neurodegenerative brain diseases. *Hum. Mutat.*, **33**, 1340-1344.
- Kasten, M., Hartmann, C., Hampf, J., Schaake, S., Westerberger, A., Vollstedt, E.J., Balck, A., Domingo, A., Vulinovic, F., Dulovic, M. et al. (2018) Genotype-phenotype relations for the Parkinson's disease genes Parkin, PINK1, DJ1: MDSGene systematic review. *Mov. Disord.*, **33**, 730-741.
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E. et al. (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.*, **17**, 405-424.
- Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M. and Sirotkin, K. (2001) dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.*, **29**, 308-311.
- Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B. et al. (2016) Analysis of protein-coding genetic variation in 60,706 humans. *Nature*, **536**, 285-291.
- Nykamp, K., Anderson, M., Powers, M., Garcia, J., Herrera, B., Ho, Y.-Y., Kobayashi, Y., Patil, N., Thusberg, J., Westbrook, M. Invitae Clinical Genomics Group, Topper, S. (2017) Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genet. Med.*, **19**, 1105-1117.
- MacArthur, D.G., Manolio, T.A., Dimmock, D.P., Rehm, H.L., Shendure, J., Abecasis, G.R., Adams, D.R., Altman, R.B., Antonarakis, S.E., Ashley, E.A. et al. (2014) Guidelines for investigating causality of sequence variants in human disease. *Nature*, **508**, 469-476.
- Wenzel, D.M., Lissounov, A., Brzovic, P.S. and Klevit, R.E. (2011) UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. *Nature*, **474**, 105-108.
- Ordureau, A., Sarraf, S.A., Duda, D.M., Heo, J.-M., Jedrykowski, M.P., Sviderskiy, V.O., Olszewski, J.L., Koerber, J.T., Xie, T., Beausoleil, S.A. et al. (2014) Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. *Mol. Cell*, **56**, 360-375.
- Koyano, F., Okatsu, K., Kosako, H., Tamura, Y., Go, E., Kimura, M., Kimura, Y., Tsuchiya, H., Yoshihara, H., Hirokawa, T. et al. (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature*, **510**, 162-166.
- Kazlauskaite, A., Kondapalli, C., Gourlay, R., Campbell, D.G., Ritoro, M.S., Hofmann, K., Alessi, D.R., Knebel, A., Trost, M. and Muqit, M.M. (2014) Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. *Biochem. J.*, **460**, 127-139.
- Kane, L.A., Lazarou, M., Fogel, A.I., Li, Y., Yamano, K., Sarraf, S.A., Banerjee, S. and Youle, R.J. (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. *J. Cell Biol.*, **205**, 143-153.
- Sauvé, V., Lilov, A., Seirafi, M., Vranas, M., Rasool, S., Kozlov, G., Sprules, T., Wang, J., Trempe, J.F. and Gehring, K. (2015) A Ubl/ubiquitin switch in the activation of Parkin. *EMBO J.*, **34**, 2492-2505.
- Sauvé, V., Sung, G., Soya, N., Kozlov, G., Blaimschein, N., Miotto, L.S., Trempe, J.-F., Lukacs, G.L. and Gehring, K. (2018) Mechanism of parkin activation by phosphorylation. *Nat. Struct. Mol. Biol.*, **25**, 623-630.
- Gladkova, C., Maslen, S.L., Skehel, J.M. and Komander, D. (2018) Mechanism of parkin activation by PINK1. *Nature*, **559**, 410-414.
- Pickles, S., Vigié, P. and Youle, R.J. (2018) Mitophagy and quality control mechanisms in mitochondrial maintenance. *Curr. Biol.*, **28**, R170-R185.
- Panicker, N., Dawson, V.L. and Dawson, T.M. (2017) Activation mechanisms of the E3 ubiquitin ligase parkin. *Biochem. J.*, **474**, 3075-3086.
- Sriram, S.R., Li, X., Ko, H.S., Chung, K.K.K., Wong, E., Lim, K.L., Dawson, V.L. and Dawson, T.M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. *Hum. Mol. Genet.*, **14**, 2571-2586.
- Wang, C., Tan, J.M., Ho, M.W., Zaiden, N., Wong, S.H., Chew, C.L., Eng, P.W., Lim, T.M., Dawson, T.M. and Lim, K.L. (2005) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. *J. Neurochem.*, **93**, 422-431.
- Hampe, C., Ardila-Osorio, H., Fournier, M., Brice, A. and Corti, O. (2006) Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. *Hum. Mol. Genet.*, **15**, 2059-2075.
- Matsuda, N., Kitami, T., Suzuki, T., Mizuno, Y., Hattori, N. and Tanaka, K. (2006) Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. *J. Biol. Chem.*, **281**, 3204-3209.
- Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.-F., Gautier, C.A., Shen, J., Cookson, M.R. and Youle, R.J. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol.*, **8**, e1000298.
- Fiesel, F.C., Caulfield, T.R., Moussaud-Lamodiere, E.L., Ogaki, K., Dourado, D.F., Flores, S.C., Ross, O.A. and Springer, W. (2015) Structural and functional impact of Parkinson disease-associated mutations in the E3 ubiquitin ligase Parkin. *Hum. Mutat.*, **36**, 774-786.
- Lill, C.M., Mashychev, A., Hartmann, C., Lohmann, K., Marras, C., Lang, A.E., Klein, C. and Bertram, L. (2016) Launching the movement disorders society genetic mutation database (MDSGene). *Mov. Disord.*, **31**, 607-609.
- Katayama, H., Kogure, T., Mizushima, N., Yoshimori, T. and Miyawaki, A. (2011) A sensitive and quantitative technique for detecting autophagic events based on lysosomal delivery. *Chem. Biol.*, **18**, 1042-1052.
- Tang, M.Y., Vranas, M., Krahn, A.I., Pundlik, S., Trempe, J.F. and Fon, E.A. (2017) Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation. *Nat. Commun.*, **8**, 14697.

30. Trempe, J.-F., Sauvé, V., Grenier, K., Seirafi, M., Tang, M.Y., Ménade, M., Al-Abdul-Wahid, S., Krett, J., Wong, K., Kozlov, G. et al. (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. *Science*, **340**, 1451–1455.
31. Kumar, A., Chaugule, V.K., Condos, T.E.C., Barber, K.R., Johnson, C., Toth, R., Sundaramoorthy, R., Knebel, A., Shaw, G.S. and Walden, H. (2017) Parkin-phosphoubiquitin complex reveals cryptic ubiquitin-binding site required for RBR ligase activity. *Nat. Struct. Mol. Biol.*, **24**, 475–483.
32. Safadi, S.S. and Shaw, G.S. (2007) A disease state mutation unfolds the parkin ubiquitin-like domain. *Biochemistry*, **46**, 14162–14169.
33. Spratt, D.E., Martinez-Torres, R.J., Noh, Y.J., Mercier, P., Manczyk, N., Barber, K.R., Aguirre, J.D., Burchell, L., Purkiss, A., Walden, H., Shaw, G.S. (2013) A molecular explanation for the recessive nature of parkin-linked Parkinson's disease. *Nat. Commun.*, **4**, 1983.
34. Rasool, S., Soya, N., Truong, L., Croteau, N., Lukacs, G.L. and Trempe, J.F. (2018) PINK1 autophosphorylation is required for ubiquitin recognition. *EMBO Rep.*, **19**:e44981.
35. Okatsu, K., Koyano, F., Kimura, M., Kosako, H., Saeki, Y., Tanaka, K. and Matsuda, N. (2015) Phosphorylated ubiquitin chain is the genuine Parkin receptor. *J. Cell Biol.*, **209**, 111–128.
36. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*, **392**, 605–608.
37. Safadi, S.S., Barber, K.R. and Shaw, G.S. (2011) Impact of autosomal recessive juvenile Parkinson's disease mutations on the structure and interactions of the parkin ubiquitin-like domain. *Biochemistry*, **50**, 2603–2610.
38. Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J. and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat. Cell Biol.*, **12**, 119–131.
39. Pickrell, A.M. and Youle, R.J. (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron*, **85**, 257–273.
40. Grenier, K., McLelland, G.L. and Fon, E.A. (2013) Parkin- and PINK1-dependent mitophagy in neurons: will the real pathway please stand up. *Front. Neurol.*, **4**, 100.
41. Whitworth, A.J. and Pallanck, L.J. (2017) PINK1/Parkin mitophagy and neurodegeneration—what do we really know in vivo. *Curr. Opin. Genet. Dev.*, **44**, 47–53.